Orrick Pharmaceuticals, founded in 2020, is a biopharmaceutical company with a strong focus on the research and development of small molecule drugs targeting diseases such as tumors and immunity. The company has a long-standing presence in the innovation of drug development, production, and sales, independently creating new drug products to meet specific clinical needs.
The company's last investment was a Series A investment at 17 January 2023, with szcgc being the investor. Orrick Pharmaceuticals operates within the Biopharma and Biotechnology industries. With its innovative approach to drug development focusing on critical medical needs, Orrick Pharmaceuticals presents an attractive investment opportunity for venture capitalists looking to support advancements in healthcare and pharmaceuticals.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | Unknown | 1 |
|
17 Jan 2023 |
No recent news or press coverage available for Orrick Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.
